118 related articles for article (PubMed ID: 3496455)
1. Natural killer cell activity in dermatomyositis-polymyositis.
Gonzalez-Amaro R; Alcocer-Varela J; Alarcón-Segovia D
J Rheumatol; 1987 Apr; 14(2):307-10. PubMed ID: 3496455
[TBL] [Abstract][Full Text] [Related]
2. Natural killer cell activity in the systemic connective tissue diseases.
Gonzalez-Amaro R; Alcocer-Varela J; Alarcón-Segovia D
J Rheumatol; 1988 Aug; 15(8):1223-8. PubMed ID: 3263500
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells.
Arahata K; Engel AG
Ann Neurol; 1984 Aug; 16(2):193-208. PubMed ID: 6383191
[TBL] [Abstract][Full Text] [Related]
4. [Natural killer (NK) cells and interleukin 2 (IL-2) in Crohn disease].
Lozano Polo JL; Echevarría Vierna S; Casafont Morencos F; Ledesma Castaño F; Pons Romero F
Rev Esp Enferm Dig; 1990 Aug; 78(2):71-5. PubMed ID: 2271297
[TBL] [Abstract][Full Text] [Related]
5. Defective natural killer (NK) and killer (K) cell function in systemic lupus erythematosus.
Ewan PW; Barrett HM; Pusey CD
J Clin Lab Immunol; 1983 Feb; 10(2):71-6. PubMed ID: 6842577
[TBL] [Abstract][Full Text] [Related]
6. Absence of responsiveness to interferon-gamma but not to interleukin 2 and depressed recycling as natural killer cell abnormalities in childhood lymphohistiocytic syndrome.
Yang FC; Yabuhara A; Koike K
Int J Hematol; 1994 Jun; 59(4):273-80. PubMed ID: 8086621
[TBL] [Abstract][Full Text] [Related]
7. Defective natural cytotoxicity in patients with cancer: normal number of effector cells but decreased recycling capacity in patients with advanced disease.
Steinhauer EH; Doyle AT; Reed J; Kadish AS
J Immunol; 1982 Nov; 129(5):2255-9. PubMed ID: 7119445
[TBL] [Abstract][Full Text] [Related]
8. Low natural killer cell cytotoxic activity in autism: the role of glutathione, IL-2 and IL-15.
Vojdani A; Mumper E; Granpeesheh D; Mielke L; Traver D; Bock K; Hirani K; Neubrander J; Woeller KN; O'Hara N; Usman A; Schneider C; Hebroni F; Berookhim J; McCandless J
J Neuroimmunol; 2008 Dec; 205(1-2):148-54. PubMed ID: 18929414
[TBL] [Abstract][Full Text] [Related]
9. Natural and antibody-dependent cellular cytotoxicity in children with systemic lupus erythematosus and juvenile dermatomyositis.
Miller ML; Lantner R; Pachman LM
J Rheumatol; 1983 Aug; 10(4):640-2. PubMed ID: 6620266
[TBL] [Abstract][Full Text] [Related]
10. Abnormal natural killer cell activity in systemic lupus erythematosus: an intrinsic defect in the lytic event.
Katz P; Zaytoun AM; Lee JH; Panush RS; Longley S
J Immunol; 1982 Nov; 129(5):1966-71. PubMed ID: 7119439
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of the damaging effect of dermatomyositis mononuclear cells on cultured human skin fibroblasts.
Saito E; Kuroda K; Yoshimoto Y; Oshima H; Kinoshita M
J Rheumatol; 1989 Aug; 16(8):1055-60. PubMed ID: 2585402
[TBL] [Abstract][Full Text] [Related]
12. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
[TBL] [Abstract][Full Text] [Related]
13. A killing defect of natural killer cells as an underlying immunologic abnormality in childhood systemic lupus erythematosus.
Yabuhara A; Yang FC; Nakazawa T; Iwasaki Y; Mori T; Koike K; Kawai H; Komiyama A
J Rheumatol; 1996 Jan; 23(1):171-7. PubMed ID: 8838528
[TBL] [Abstract][Full Text] [Related]
14. Natural killer cell activity in families of patients with systemic lupus erythematosus: demonstration of a killing defect in patients.
Green MR; Kennell AS; Larche MJ; Seifert MH; Isenberg DA; Salaman MR
Clin Exp Immunol; 2005 Jul; 141(1):165-73. PubMed ID: 15958083
[TBL] [Abstract][Full Text] [Related]
15. Depressed natural killer cell activity in acute myocardial infarction.
Klarlund K; Pedersen BK; Theander TG; Andersen V
Clin Exp Immunol; 1987 Oct; 70(1):209-16. PubMed ID: 3500813
[TBL] [Abstract][Full Text] [Related]
16. Interleukin (IL)-2 deficiency aggravates the defect of natural killer cell activity in AIDS patients.
Zerhouni B; Sanhadji K; Kehrli L; Livrozet JM; Touraine JL
Thymus; 1997; 24(3):147-56. PubMed ID: 9151380
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-6 (IL-6) expression and natural killer (NK) cell dysfunction and anergy in heart failure.
Vredevoe DL; Widawski M; Fonarow GC; Hamilton M; Martínez-Maza O; Gage JR
Am J Cardiol; 2004 Apr; 93(8):1007-11. PubMed ID: 15081444
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibody analysis of mononuclear cells in myopathies. IV: Cell-mediated cytotoxicity and muscle fiber necrosis.
Arahata K; Engel AG
Ann Neurol; 1988 Feb; 23(2):168-73. PubMed ID: 3288082
[TBL] [Abstract][Full Text] [Related]
19. Preservation of natural killer and interleukin-2 activated killer cell activity in ataxia-telangiectasia with T cell deficiency.
Tsuge I; Matsuoka H; Torii S; Okada J; Mizuno T; Matsuoka M; Kodera Y; Takahashi T
J Clin Lab Immunol; 1987 May; 23(1):7-13. PubMed ID: 3497277
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation.
Porrata LF; Inwards DJ; Lacy MQ; Markovic SN
Bone Marrow Transplant; 2001 Oct; 28(7):673-80. PubMed ID: 11704790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
